TY - JOUR
T1 - Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes
AU - MacLeod, Erin L.
AU - Gleason, Sally T.
AU - van Calcar, Sandra C.
AU - Ney, Denise M.
N1 - Funding Information:
This research was supported by NIH grants R03-DK-071534 and P30-HD-03352 . The authors would like to thank Dr. Murray Clayton for guidance with statistical analysis; Dr. Gregory Rice and Lisa Bingen, MS, RD for reviewing the manuscript; and all of the subjects with PKU who participated in the study.
PY - 2009/12
Y1 - 2009/12
N2 - Lifelong treatment of phenylketonuria (PKU) includes a phenylalanine (phe) restricted diet that provides sufficient phe for growth and maintenance plus phe-free amino acid formula to meet requirements for protein, energy and micronutrients. Phe tolerance (mg phe/kg body weight/day) is the amount of phe those with PKU can consume and maintain acceptable blood phe levels; it requires individual assessment because of varying phenylalanine hydroxylase activity. The objective was to reassess phe tolerance in eight adults with PKU considering phe requirements, blood phe levels, genotype and phe tolerance at 5 years of age. Subjects had not received a personalized assessment of phe tolerance in several years, and five subjects were overweight, body mass index (BMI) 25-28. With the guidance of a metabolic dietitian, seven subjects increased phe tolerance (by 15-173%) without significantly increasing blood phe concentration. Increased phe tolerance was associated with both improved dietary compliance and inadequate phe intake at the onset of the protocol compared with current requirements. Improved dietary compliance reflected increased consumption of protein equivalents from amino acid formula and increased frequency of formula intake, from 2.2 to 3 times per day. Predictors of higher final phe tolerance following reassessment included being male and having a lower BMI (R2 = 0.588). This suggests that the rising trend of overweight and obesity may affect assessment of phe tolerance in adults. Therefore, interaction with the metabolic dietitian to reassess phe tolerance in relation to body mass is essential throughout adulthood to insure adequate intake of phe to support protein synthesis and prevent catabolism.
AB - Lifelong treatment of phenylketonuria (PKU) includes a phenylalanine (phe) restricted diet that provides sufficient phe for growth and maintenance plus phe-free amino acid formula to meet requirements for protein, energy and micronutrients. Phe tolerance (mg phe/kg body weight/day) is the amount of phe those with PKU can consume and maintain acceptable blood phe levels; it requires individual assessment because of varying phenylalanine hydroxylase activity. The objective was to reassess phe tolerance in eight adults with PKU considering phe requirements, blood phe levels, genotype and phe tolerance at 5 years of age. Subjects had not received a personalized assessment of phe tolerance in several years, and five subjects were overweight, body mass index (BMI) 25-28. With the guidance of a metabolic dietitian, seven subjects increased phe tolerance (by 15-173%) without significantly increasing blood phe concentration. Increased phe tolerance was associated with both improved dietary compliance and inadequate phe intake at the onset of the protocol compared with current requirements. Improved dietary compliance reflected increased consumption of protein equivalents from amino acid formula and increased frequency of formula intake, from 2.2 to 3 times per day. Predictors of higher final phe tolerance following reassessment included being male and having a lower BMI (R2 = 0.588). This suggests that the rising trend of overweight and obesity may affect assessment of phe tolerance in adults. Therefore, interaction with the metabolic dietitian to reassess phe tolerance in relation to body mass is essential throughout adulthood to insure adequate intake of phe to support protein synthesis and prevent catabolism.
KW - Amino acid requirements
KW - Genotype-phenotype relationship
KW - Low-phenylalanine diet
KW - PKU
UR - http://www.scopus.com/inward/record.url?scp=70350620454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350620454&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2009.07.016
DO - 10.1016/j.ymgme.2009.07.016
M3 - Article
C2 - 19747868
AN - SCOPUS:70350620454
SN - 1096-7192
VL - 98
SP - 331
EP - 337
JO - Biochemical Medicine and Metabolic Biology
JF - Biochemical Medicine and Metabolic Biology
IS - 4
ER -